The use of alendronic acid in the treatment of osteoporosis


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Bisphosphonates are the most common drugs used for the treatment of osteoporosis. The article examines the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of alendronates from the perspective of evidence-based medicine. The feasibility of the application of alendronate 70 mg once a week, which significantly improves patients' adherence to treatment, is demonstrated.

Texto integral

Acesso é fechado

Bibliografia

  1. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации / Под ред. О.М. Лесняк, Л.И. Беневоленской. М., 2009. С. 98-121.
  2. Compston J.E. The therapeutic use of bisphosphonates. BMJ. 1994;309(6956):711-15.
  3. Pols H.A., Felsenberg D., Hanley D.A., Stepan I., Munoz-Torres M., Wilkin T.J. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos. Int. 1999;9(5):461-68.
  4. Black D.M., Reiss T.F., Nevitt M.C., Cauley J., Karpf D., Cummings S.R. Design of the Fracture Intervention Trial. Osteoporos Int. 1993;3(Suppl 3):S29-39.
  5. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41.
  6. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates A.J., LaCroix A.Z. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24): 2077-82.
  7. Geusens P. Bisphosphonates for postmenopaus al. osteoporosis: determining duration of treatment. Curr. Osteoporos Rep. 2009;7(1):12-7.
  8. Ершова О.Б., Назарова А.В. Бисфосфонаты -продолжительность использования при остеопорозе, целесообразность и безопасность. Фарматека, 2013;7:78-80.
  9. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 2010;95(4):1555-65.
  10. Diab D.L., Watts N.B. Bisphosphonates in the treatment of osteoporosis. Endocrinol. Metab. Clin. North. Am. 2012;41(3):487-506.
  11. Black D.M., Schwartz A.V., Ensrud K.E., et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-38.
  12. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C. 2nd, Kaur A., Thompson D.E., Yates J., Orloff J.J. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12(1):1-12.
  13. Rizzoli R., Greenspan S.L., Bone G. 3rd, Schnitzer T.J., Watts N.B., Adami S., Foldes A.J., Roux C., Levine M.A., Uebelhart B., Santora A.C. 2nd, Kaur A., Peverly C.A., Orloff J.J. Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J. Bone Miner. Res. 2002;17(11):1988-96.
  14. Greenspan S., Field-Munves E., Tonino R., Smith M., Petruschke R., Wang L., Yates J., de Papp A.E., Palmisano J. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin. Proc. 2002;77(10):1044-52.
  15. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin. Ther. 2002;24(11):1871-86.
  16. Nguyen D.M., Schwartz J., Richardson P., El-Serag H.B. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig. Dis. Sci. 2010;55(12):3404-07.
  17. Olson K., Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J. Oncol. Pharm. Pract. 2007;13(4):223-29.
  18. Dicuonzo G., Vincenzi B., Santini D., Avvisati G., Rocci L., Battistoni F., Gavasci M., Borzomati D., Coppola R., Tonini G. Fever after zoledronic acid administration is due to Increase in TNF-alpha and IL-6. J. Interferon Cytokine Res. 2003;23(11):649-54.
  19. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate Related Osteonecrosis of the Jaws. 2006. J. Oral Maxillofac. Surg. 2007;65(12):2397-410.
  20. Скрипникова И.А., Рожинская Л.Я. Применение дженериков - способ повышения приверженности лечению остеопороза. Остеопороз и остеопатии. 2010;3:36-40.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2015

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies